This study is looking at how well two drugs, T-DM1 and tucatinib, work to stop breast cancer from coming back in people with a high risk of the disease. T-DM1 is a type of treatment that combines a targeted therapy, trastuzumab, with a chemotherapy drug, DM1, to attack specific cancer cells. Tucatinib works by blocking enzymes that help cancer cells grow. The study compares the effectiveness of using both drugs together versus using T-DM1 alone. Participants will be randomly assigned to receive either both drugs or just T-DM1 and a placebo.
Key Points:
- The study lasts for up to 14 cycles, with each cycle being 21 days long.
- Participants will need to attend follow-up visits every 6 months for 10 years after treatment.
- Compensation or specific risks are not mentioned, but participants should discuss with their doctors.
How understandable was the trial content above?
Hard to understand
Easy to understand